title: Prognostic value of Ezrin in solid tumors: a meta-analysis of the literature.
abstract: OBJECTIVE
  Ezrin is a cytoskeletal protein involved in tumor growth and invasion. However its prognostic value for survival in patients with solid tumor remains controversial.
  
  
  METHODS
  Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.
  
  
  RESULTS
  Twenty-seven eligible trials involving 4693 patients were ultimately identified. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive Ezrin expression had an impact on overall survival (OS) [1.95, 95% confidence interval (CI) 1.60-2.39; P<0.001] in all eligible studies and progress free survival (PFS): (2.30 95% CI 1.0-3.61; P = 0.001). Similar results were also observed in subgroup analysis, according to tumor types, regions, patients' number and publication year.
  
  
  CONCLUSIONS
  Our findings suggested that Ezrin protein expression might be a factor for a poor prognosis in patients with solid tumor. So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.
authors.affiliation: Department of Oncology, Shanghai Sixth People's Hospital East Campus, Shanghai Jiao Tong University, Shanghai, China.
authors.forename: Kun
authors.initials: K
authors.lastname: Han
authors.forename: WeiXiang
authors.initials: W
authors.lastname: Qi
authors.forename: ZhiHua
authors.initials: Z
authors.lastname: Gan
authors.forename: Zan
authors.initials: Z
authors.lastname: Shen
authors.forename: Yang
authors.initials: Y
authors.lastname: Yao
authors.forename: DaLiu
authors.initials: D
authors.lastname: Min
mesh_terms: D003598:Cytoskeletal Proteins / Q000378:metabolism*; D006801:Humans; D009369:Neoplasms / Q000378:metabolism* / Q000401:mortality*; D011379:Prognosis; D016016:Proportional Hazards Models; D017594:Publication Bias; D000099149:Ezrin
chemical_list: D003598:Cytoskeletal Proteins; D000099149:Ezrin
references.citation: Hum Pathol. 2008 Dec;39(12):1737-43
references.pmid: 18701134
references.citation: Mod Pathol. 2006 Apr;19(4):581-7
references.pmid: 16554733
references.citation: Ann Surg Oncol. 2010 Dec;17(12):3212-9
references.pmid: 20585869
references.citation: Hum Pathol. 2011 Mar;42(3):384-92
references.pmid: 21190723
references.citation: J Clin Pathol. 2011 Aug;64(8):689-94
references.pmid: 21653656
references.citation: Nat Med. 2004 Feb;10(2):175-81
references.pmid: 14704789
references.citation: Arch Surg. 2005 Dec;140(12):1184-90
references.pmid: 16365240
references.citation: J Clin Pathol. 2007 Feb;60(2):185-9
references.pmid: 16698950
references.citation: Mol Carcinog. 2010 Sep;49(9):798-804
references.pmid: 20572160
references.citation: Clin Cancer Res. 2005 Sep 1;11(17):6198-204
references.pmid: 16144921
references.citation: Gynecol Oncol. 2003 Aug;90(2):273-81
references.pmid: 12893187
references.citation: J Surg Oncol. 2011 Oct;104(5):538-43
references.pmid: 21416469
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Nat Med. 2004 Feb;10(2):182-6
references.pmid: 14704791
references.citation: Int J Gynecol Pathol. 2006 Apr;25(2):121-30
references.pmid: 16633060
references.citation: Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99
references.pmid: 12154370
references.citation: Tumour Biol. 2011 Aug;32(4):707-12
references.pmid: 21625943
references.citation: Int J Colorectal Dis. 2012 Jul;27(7):893-9
references.pmid: 22234584
references.citation: Korean J Pathol. 2012 Oct;46(5):470-7
references.pmid: 23136574
references.citation: Cancer Cell. 2004 Feb;5(2):113-4
references.pmid: 14998486
references.citation: BMJ. 2001 Jul 28;323(7306):224-8
references.pmid: 11473921
references.citation: Breast Cancer Res. 2005;7(3):R365-73
references.pmid: 15987432
references.citation: Head Neck. 2006 Nov;28(11):1018-27
references.pmid: 16783828
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Jul;112(1):96-104
references.pmid: 21550270
references.citation: Pathol Oncol Res. 2011 Dec;17(4):827-33
references.pmid: 21465252
references.citation: Colorectal Dis. 2011 Sep;13(9):989-98
references.pmid: 20718834
references.citation: Nat Rev Cancer. 2003 Nov;3(11):877-83
references.pmid: 14668818
references.citation: Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2442-9
references.pmid: 11581181
references.citation: Chin Med J (Engl). 2013 Jan;126(2):242-7
references.pmid: 23324271
references.citation: Am J Surg Pathol. 2011 Apr;35(4):590-8
references.pmid: 21412073
references.citation: Head Neck Pathol. 2012 Jun;6(2):232-43
references.pmid: 22228071
references.citation: J Biol Chem. 2009 Mar 20;284(12):7995-8004
references.pmid: 19164283
references.citation: BMJ. 2009 Jul 21;339:b2535
references.pmid: 19622551
references.citation: Am J Transl Res. 2011 Feb;3(2):209-18
references.pmid: 21416062
references.citation: Eur Urol. 2009 Nov;56(5):829-36
references.pmid: 18926620
references.citation: EMBO J. 2001 Jun 1;20(11):2723-41
references.pmid: 11387207
references.citation: J Biol Chem. 2004 Jun 18;279(25):26280-6
references.pmid: 15096511
references.citation: Pathol Oncol Res. 2011 Dec;17(4):909-15
references.pmid: 21717114
references.citation: Mod Pathol. 2009 Oct;22(10):1351-60
references.pmid: 19648886
references.citation: Stat Med. 1998 Dec 30;17(24):2815-34
references.pmid: 9921604